The initial evidence revealing the association between SUMOylation and cancer derived from the identification of the promyelocytic leukemia protein (PML) and the oncogenic fusion protein PML—retinoic acid receptor-α (RARα) as SUMO substrates [21]. This evidence concerns the gene RARA and cancer.